media – Page 665 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Blockchain System Aims to Identify Health Problems Using AI

A new Blockchain platform has seemingly proven that it is possible to for AI to perform more accurate health diagnosis than human doctors, paving the way for a change in the way medical tests are performed.
- Source: Cointelegraph
- 785
- April 12, 2018
AI digital health Market Views
Strong Growth Potential in Global Clinical Trial Data Management and eClinical Solutions Market to Cross $4 Billion by 2020

Unified cloud-based eClinical platforms, with built-in scalability and modularity, will drive growth opportunities across the globe
- Source: PR Newswire
- 784
- April 12, 2018
Clinical Trial Market Views mHealth
Cleveland Clinic Targets Telemedicine, Big Data and AI to Improve the Future of Care

The healthcare leader relies on digital platforms, a closer relationship with IBM to continue to fast-forward care.
- Source: HealthTech Magazine
- 760
- April 12, 2018
digital health health IT Researches
FDA Prolongs Review Date for AbbVie Endometriosis Candidate

The FDA extends the review period of NDA for AbbVie (ABBV) and partner Neurocrine Biosciences' endometriosis candidate, elagolix, by three months to third-quarter 2018.
- Source: finance.yahoo
- 680
- April 12, 2018
elagolix endometriosis New Approvals
Illumina and Loxo Oncology to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics

Illumina, Inc. (Nasdaq: ILMN) and Loxo Oncology (Nasdaq: LOXO) today announced a global strategic partnership to develop and commercialize a multi-gene panel for broad tumor profiling, resulting in a distributable, next-generation sequencing (NGS) based companion diagnostic (CDx) with a pan-cancer indication.
- Source: Illumina
- 685
- April 12, 2018
larotrectinib Market Views
Alexion to buy Wilson for $855m

Alexion Pharmaceuticals has offered to buy Wilson Therapeutics in a deal worth around $855 million. Wilson is a Swedish biopharma developing novel therapies for patients with rare copper-mediated disorders.
- Source: pharmatimes
- 567
- April 12, 2018
Alexion Market Views rare copper-mediated disorders
Novartis’ Afinitor Disperz wins new TSC-related approval

Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
- Source: pharmatimes
- 855
- April 12, 2018
Afinitor Disperz New Approvals Novartis TSC
Ionis and AstraZeneca Advance New Drug for NASH

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (NYSE: AZN) following advancement of the drug into development. IONIS-AZ6-2.5-LRx is designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis (NASH)
- Source: Prnewswire
- 732
- April 11, 2018
Market Views NASH
FDA restricts sales of a Bayer’s Essure birth control device

The Food and Drug Administration(FDA) moved Monday to put sales restrictions on a Bayer birth control implant that has been a target of consumer criticism.
- Source: Usatoday
- 624
- April 11, 2018
Company Insights contraceptive device
FDA Approves Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

On April 6, 2018, the Food and Drug Administration(FDA) approved rucaparib (Rubraca®, Clovis Oncology Inc.), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- Source: asco.org
- 664
- April 11, 2018
FDA New Approvals rucaparib

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.